acute coronary disease
Conditions
Interventions
STEMI:180mg ticagrelor
NSTEMI:180mg ticagrelor
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
19 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients admitted with diagnosis of STEMI, within 12-48 h from the onset of symptoms, and not eligible for a primary PCI strategy would be enrolled into the STEMI group. At the same time, patients admitted with diagnosis of Non STsegment elevation myocardial infarction (NSTEMI), within 48h from the last onset of symptoms would be enrolled into the NSTEMI group.
Exclusion criteria
Exclusion criteria: 1. age =18 years; 2. active bleeding or bleeding diathesis or history of significant gastrointestinal bleed within 1 year; 3. any previous transient ischemic attack/stroke or history of intracranial hemorrhage; 4. administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor; 5. known relevant hematological deviations; 6. life expectancy =1 year; 7. known severe liver or renal diseases; 8. patients with cardiogenic shock; 9. patients who are unable to swallow drug or vomit after intake ; 10. active cancer; 11. need for urgent revascularization; 12. patients with sick sinus syndrome, 2nd or 3rd degree atrioventricular block; 13. need treatment with oral anticoagulant; 14. known, clinically important thrombocytopenia(i.e. <100*109/L) or anaemia (i.e. <100g/L); 15. pregnancy or lactation; 16. any contraindication against the use of ticagrelor; 17. Concomitant use of morphine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IPA; | — |
Countries
China
Contacts
Public ContactQian Juying
Zhongshan Hospital, Fudan University
Outcome results
None listed